GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedPacto Inc (XKRX:235980) » Definitions » Institutional Ownership

MedPacto (XKRX:235980) Institutional Ownership : 1.67% (As of Mar. 25, 2025)


View and export this data going back to 2019. Start your Free Trial

What is MedPacto Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MedPacto's institutional ownership is 1.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MedPacto's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MedPacto's Float Percentage Of Total Shares Outstanding is 0.00%.


MedPacto Institutional Ownership Historical Data

The historical data trend for MedPacto's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedPacto Institutional Ownership Chart

MedPacto Historical Data

The historical data trend for MedPacto can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Institutional Ownership 3.31 2.97 2.93 2.92 2.62 2.53 2.53 2.59 2.38 1.67

MedPacto Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


MedPacto Business Description

Traded in Other Exchanges
N/A
Address
92 Myeongdal -ro, Seocho-gu, Borim Building, Seoul, KOR
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.

MedPacto Headlines

No Headlines